HAMLET Pharma Appoints Issa PR to Launch First Major Clinical Trials for a New Cancer Killing Molecule
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor
LY09004 Approved for Clinical Trials in China, Luye Pharma Steps-up Global R&D Investment in Biopharma Medicines
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
Lipella Pharmaceuticals Received FDA IND Approval for Phase-2a Oncology Supportive Care Drug Study
- Advertisement -